Clinical trials: Antitumor Drug
Breast Cancer, Ovarian Cancer
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
This is a Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PF-07224826, as a single agent or in…
- Conditions
- Breast Cancer, Ovarian Cancer, Liposarcoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05905341
- Testing
- PF-07224826, Fulvestrant
- Sponsor
- Pfizer
Solid Tumor (Phase I), RAS Mutation
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
The goal of this clinical trial is to determine whether AN4035 is safe and tolerable in people with advanced or metastatic solid tumors that have Rat Sarcoma oncogene (RAS) mutated solid tumors and high levels of the CEACAM5…
- Conditions
- Solid Tumor (Phase I), RAS Mutation, CEACAM5
- Trial name
- NCT07686445
- Testing
- Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor.
- Where
- 2 sites in Australia
- Volunteers
- 228 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Advanced or Metastatic Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid…
- Trial name
- NCT06752681
- Testing
- DAY301
- Where
- 11 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Solid Tumor
PRECISE CURATE.AI Pilot Clinical Trial
In the current clinical context, drug dosing in oncology is dictated by toxicity. The optimal dosages of drugs in combinatory regimens for solid tumours are not clear, and the typical physician's decision on dose adjustment is a…
- Trial name
- NCT04522284
- Testing
- CURATE.AI, Capecitabine, XELOX
- Where
- 2 sites in Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Internal and External Contamination of Physiotherapists by Antineoplastic Drugs
Occupational Exposure to Antineoplastic Drugs Among Physiotherapists in Healthcare Settings
Many antineoplastic drugs are considered "hazardous to handle" for healthcare professionals, notably because of their carcinogenic, mutagenic and/or reprotoxic effects.
- Trial name
- KINEMAC (NCT07328464)
- Testing
- urine sample, dermal wipe sampling, questionnaires
- Where
- 2 sites in France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Chemotherapeutic Agent Toxicity, Neuropathy
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary…
- Conditions
- Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain
- Trial name
- NCT02311907
- Testing
- Carboplatin, Glutathione, Laboratory Biomarker Analysis
- Where
- 390 sites in United States
- Volunteers
- 195 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adherence, Patient, Cancer
Impact of Changing the Appearance of Oral Antineoplastics on Adherence and Continuity of Treatment, Patient-reported Health Outcomes, and Patient Experience of Care
Oral chemotherapy is a convenient and flexible option for cancer treatment that can improve patients quality of life and increase adherence to treatment compared to traditional intravenous chemotherapy.
- Trial name
- NCT07664683
- Where
- Spain
- Volunteers
- 334 people
- Sponsor
- Universidad Miguel Hernandez de Elche
Sarcoma, Kaposi, HIV Infections
Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
- Trial name
- NCT00002226
- Testing
- SU5416
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
Solid Tumor, Adult
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198.
- Trial name
- NCT06507306
- Testing
- KQB198, Osimertinib, Amivantamab
- Where
- 26 sites in United States, France and 2 more
- Volunteers
- 92 people
- Sponsor
- Kumquat Biosciences Inc.
Breast Neoplasm, Antineoplastic Agents
Anlotinib in Metastatic HER2 Negative Breast Cancer
The hypothesis of this study is to discover if the anlotinib can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.
- Conditions
- Breast Neoplasm, Antineoplastic Agents, Anlotinib
- Trial name
- NCT04002284
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peng Yuan
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
This phase II trial studies the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor…
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma
- Trial name
- NCT04595747
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and…
- Trial name
- NCT06106945
- Testing
- AZD0305, Elranatamab, Pomalidomide
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Advanced Breast Cancer
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Our study is aimed to evaluate the efficacy and safety of SHR-A2102 combined other antitumor treatments in advanced breast cancer.
- Trial name
- NCT07041437
- Testing
- SHR-A2102, Adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Antineoplastic Chemotherapy Induced Anemia
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
The purpose of this study is to assess safety and efficacy of weekly epoetin alfa (Hemax® ) administered for 12 weeks in patients with non curable solid tumors or lymphoma with anemia (hemoglobin < 10g/dl) undergoing palliative…
- Trial name
- NCT01374373
- Testing
- Epoetin alfa
- Where
- 3 sites in Argentina
- Volunteers
- 30 people
- Sponsor
- Bio Sidus SA
Solid Tumor
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in…
- Trial name
- NCT04931823
- Testing
- CPO-100
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell…
- Conditions
- Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
- Trial name
- NCT03972527
- Testing
- Photobiomodulation, Routine Oral Care and Analgesia
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- MuReva Phototherapy Inc.
Brest Cancer, Abemaciclib
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
Overall survival at 8 years under treatment for localized hormone-dependent breast cancer is 93.3% (1). Adjuvant therapy, especially hormone therapy, helps reduce the risk of recurrence.
- Conditions
- Brest Cancer, Abemaciclib, Adjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols
- Trial name
- MONARCHE29 (NCT06621459)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Brest
Lymphoma, Non-Hodgkin, HIV Infections
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine (AZT) treatment for patients with peripheral lymphoma.
- Trial name
- NCT00000703
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)